COMMUNIQUÉS West-GlobeNewswire

-
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
12/06/2024 -
NANOBIOTIX ORGANISE UNE DISCUSSION VIRTUELLE ENTRE EXPERTS SUR LE POTENTIEL DE NBTXR3 EN IMMUNOTHÉRAPIE DANS LE CANCER DE LA TÊTE ET DU COU ET D’AUTRES INDICATIONS LE 18 JUIN 2024
12/06/2024 -
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
12/06/2024 -
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/06/2024 -
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12/06/2024 -
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
12/06/2024 -
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12/06/2024 -
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
12/06/2024 -
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
12/06/2024 -
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
12/06/2024 -
Clearday Supports National Health Observances
12/06/2024 -
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
12/06/2024 -
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12/06/2024 -
Tevogen Bio Set to Join Russell 3000® Index
12/06/2024 -
Entourage Announces Results of 2024 Annual General Meeting of Shareholders
12/06/2024 -
Sanofi: Information concerning the total number of voting rights and shares – May 2024
12/06/2024 -
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024
12/06/2024 -
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
12/06/2024 -
Building Awareness of Mental Health Issues in the Workplace: River Oaks Treatment Center Executive Speaks at Tampa LGBT Chamber of Commerce Luncheon
12/06/2024
Pages